Further re Subscription and Issue of Equity

RNS Number : 2935J

Advanced Oncotherapy PLC

09 April 2020

 

9 April 2020

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Further re Subscription and Issue of Equity in lieu of fees

Further to the announcement made earlier today, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that several directors have subscribed for, in aggregate, 760,000   Subscription Shares at the Issue Price as part of the Subscription.

Details of the participation by certain directors in the Subscription is set out below.

In addition, a number of the Directors have agreed to receive shares in lieu of salaries, fees and bonuses owed, details of which are set out below. This will result in the issue of 825,944 new ordinary shares ("New Ordinary Shares") at the Issue Price. 

Director	Number of Subscription Shares	Number of New Ordinary Shares
Michael Sinclair (Executive Chairman)	400,000	265,944
Enrico Vanni (Non-Executive Director)	300,000	120,000
Gabriel Urwitz (Non-Executive Director)	60,000	-
Stephen Myers (Executive Director)	-	200,000
Nick Plowman (Non-Executive Director)	-	120,000
Hans Von Celsing (Non-Executive Director)	-	120,000

Further, a number of senior management have agreed to receive shares in lieu of bonuses owed. This will result in the additional issue of 65,542 New Ordinary Shares at the Issue Price.

The definitions that apply throughout this announcement are as set out in the announcement made earlier today.  

Admission and Total Voting Rights

Application will be made for the New Ordinary Shares   to be admitted to trading on AIM and it is expected that admission will take place on or around 15 May 2020 ("Admission").

Upon Admission, the Company's enlarged issued share capital will comprise 305,644,992 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 305,644,992.

The aforementioned figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.

- ENDS -

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad & Broker)
Nick Athanas / Liz Kirchner / Nicholas Chambers	Tel: [phone]
FTI Consulting (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

Notes for Editors

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities
a)	Name	PDMRs: Michael Sinclair Executive Chairman Enrico Vanni Non-Executive Director Gabriel Urwitz Non-Executive Director
2	Reason for the notification
a)	Position/status	See 1a) above
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Advanced Oncotherapy plc
b)	LEI	213800LUDHZOG3YT6C82
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 25p each in Advanced Oncotherapy plc Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109
b)	Nature of the transaction	Participation in a fundraise
c)	Price(s) and volume(s)	Price: 25p Volumes: Michael Sinclair 400,000 Enrico Vanni 300,000 Gabriel Urwitz 60,000
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	9 April 2020
f)	Place of the transaction	Outside a Trading Venue

1	Details of the person discharging managerial responsibilities
a)	Name	PDMRs: Michael Sinclair Executive Chairman Enrico Vanni Non-Executive Director Gabriel Urwitz Non-Executive Director Nick Plowman Non-Executive Director Hans Von Celsing Non-Executive Director Stephen Myers Executive Director
2	Reason for the notification
a)	Position/status	See 1a) above
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Advanced Oncotherapy plc
b)	LEI	213800LUDHZOG3YT6C82
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 25p each in Advanced Oncotherapy plc Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109
b)	Nature of the transaction	Issue of ordinary shares in consideration of payment of fees/bonuses
c)	Price(s) and volume(s)	Price: 25p Volumes: Michael Sinclair 265,944 Enrico Vanni 120,000 Stephen Myers 200,000 Nick Plowman 120,000 Hans Von Celsing 120,000
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	9 April 2020
f)	Place of the transaction	Outside a Trading Venue

 

END

 

 

FURSSWEEAESSEIL